The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia
Status:
Completed
Trial end date:
2016-12-11
Target enrollment:
Participant gender:
Summary
Background: Patient with stage 3 or 4 chronic kidney disease (CKD) usually has normal level
of serum phosphate, due to increased serum fibroblast growth factor-23 (FGF23) level that
resulted in increased phosphate urine excretion. On the other hand, serum FGF23 elevation was
related to CKD progression, vascular calcification, cardiomegaly, and mortality. This double
blind, randomized controlled trial study was conducted to evaluate effectiveness and safety
of calcium carbonate administration in stage 3 or 4 CKD patients with normophosphatemia.
Hypothesis: Calcium carbonate administration is effective and safe in chronic kidney disease
(CKD) with normophosphatemia.